(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 January 2012 (19.01.2012)

PCT

(10) International Publication Number
WO 2012/007896 A1

(51) **International Patent Classification**:
A61K 47/48 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01)

(21) **International Application Number**:
PCT/IB2011/053092

(22) **International Filing Date**:
11 July 2011 (11.07.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/363,507 12 July 2010 (12.07.2010) US

(71) **Applicant** *(for all designated States except US)*: **COVX TECHNOLOGIES IRELAND, LTD.** [IE/IE]; Pottery Road Dun Laoghaire, County Dublin (IE).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BHAT, Abhijit Suresh** [IN/US]; CovX Technologies Ireland Limited 9381, Judicial Drive, Suite 200, San Diego, California 92121 (US). **BRADSHAW, Curt William** [US/US]; 7980 Purple Sage, San Diego, California 92127 (US). **LAURENT, Olivier Alexandre** [FR/US]; CovX Technologies Ireland Limited 9381, Judicial Drive, Suite 200, San Diego, California 92121 (US). **PRESTON, Richard Ryan** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive, Suite 200, San Diego, California 92121 (US). **TUMELTY, David** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive, Suite 200, San Diego, CA 92121 (US). **WOOD, Lauren Diane** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive, Suite 200, San Diego, California 92121 (US). **YU, Wei Hong** [US/US]; CovX Technologies Ireland Limited 9381, Judicial Drive, Suite 200, San Diego, California 92121 (US). **LEE, Alice** [CN/US]; CovX Technologies Ireland Limited 9381, Judicial Drive, Suite 200, San Diego, California 92121 (US).

(74) **Agent**: **BENSON, Gregg C.**; Pfizer Inc., Eastern Point Road, MS 9114, Groton, Connecticut 06340 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: MULTIFUNCTIONAL ANTIBODY CONJUGATES

(57) **Abstract**: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CLκ) comprising K^{188} according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K^{188}, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

WO 2012/007896 A1